Poznan University of Medical Science

POZNAN, Poland--( BUSINESS WIRE )--Poznan University of Medical Sciences (PUMS), one of Poland’s leading institutions to train aspiring doctors, is expanding its partnership with global educational services provider Kaplan to provide students with an even more powerful and diverse suite of services. Effective immediately, medical and dental students will have access to Kaplan resources from the first day of their academic journey through graduation. And beginning this spring, all third year PUMS medical students will enroll in a hybrid on-campus/live online class for the USMLE ®, the multi-step licensing exam to practice medicine in the United States, to be led by Kaplan instructors. This will be in addition to the digital prep assets for the USMLE that PUMS students already have access to at the start of their third year. With the upcoming changes to Polish medical education curriculum, PUMS administrators, faculty, and students stand to benefit from resources such as Kaplan’s Educator Portal and, Quiz Builder, as well as Kaplan’s commitment to developing a Curriculum Alignment strategy for the country and PUMS. Kaplan will also begin to provide aspiring physicians at PUMS with access to i-Human Patients by Kaplan , a leader in cloud-based, interactive patient encounter simulations for medical and nursing professionals. This addition allows students to experience safe, repeatable, fully-graded clinical patient encounters on their devices anywhere, anytime. Additionally, as part of the expanded partnership, students will be able to prepare more comprehensively for the INBDE ®, the newer exam for dental licensure in the United States, with Kaplan’s suite of digital resources, such as the INBDE Board Prep & Case Review and QBank, which includes more than 2,600 highly realistic, image-based questions. Detailed performance reports will show students their individual strengths and weaknesses. “One of our main goals as a university has always been educating highly competent, skilled, and employable medical professionals, who meet the highest professional requirements in Poland and abroad. Over the years, the robust resources provided to us by Kaplan have proven to be very efficient in helping us achieve this goal. We have experienced a significant improvement in our USMLE Step 1 pass rates and have seen stronger results on other national licensure examinations since introducing Kaplan’s tools and courses to our international student cohort over 10 years ago,” said the director of the Center for Medical Education in English at PUMS, Professor Aleksandra Uruska. “We are looking forward to building on this success and developing our cooperation further for the benefit of our students and graduates.” “Kaplan has a long history of working with PUMS to support Poznan students preparing for their medical and dental licensure exams and we couldn’t be more excited about expanding our resource offerings with them,” said Jason De La Rosa, international director of institutional partnerships, Kaplan. “PUMS has a proud record of achievement, boasting of one of the highest USMLE pass rates in Poland and we look forward to building on that success story by further integrating with their curriculum.” Test names and other trademarks are the property of the respective trademark holders. About PUMS Poznan University of Medical Sciences (PUMS) stands as a renowned Polish public university that pioneered English-language medical education in Poland 30 years ago. The University adopts practical, hands-on teaching methodology, utilizing a network of five clinical hospitals, and cutting-edge simulation centers. The University is a home for 7,000 students, including 800 individuals from diverse international backgrounds in its three English-language programs: Medicine, Dentistry, and a research PhD program. Employing innovative educational and evaluation techniques, PUMS ensures students receive a comprehensive learning experience. The university maintains a 6:1 student-to-faculty ratio, guaranteeing personalized attention and mentorship for every student. With over 3,000 international graduates actively contributing to healthcare on several continents, and a growing list of international institutional partnerships, PUMS holds the highest international professional standards and recognition as one of its top priorities. Learn more at pums.edu.pl . About Kaplan Kaplan, Inc. is a global educational services company that helps individuals and institutions advance their goals in an ever-changing world. Our broad portfolio of solutions help students and professionals further their education and careers, universities and educational institutions attract and support students, and businesses maximize employee recruitment, retainment, and development. Stanley Kaplan founded our company in 1938 with a mission to expand educational opportunities for students of all backgrounds. Today, our thousands of employees working in 26 countries continue Stanley’s mission as they serve about 1.2 million students and professionals, 13,000 corporate clients, and 4,000 schools, school districts, colleges, and universities worldwide. Kaplan is a subsidiary of the Graham Holdings Company (NYSE: GHC). Learn more at kaplan.com . Note to editors: Kaplan is a subsidiary of Graham Holdings Company (NYSE: GHC) X: @PUMS_tweets , @KaplanEdNews

遗传信息由组蛋白包装在细胞核中，这允许DNA分子在有限的核空间内进行必要的紧凑。组蛋白的八聚体(由两个拷贝的H_2A、H_2B、H_3和H_4组成)构成核小体的核心 遗传信息由组蛋白包装在细胞核中，这允许DNA分子在有限的核空间内进行必要的紧凑。组蛋白的八聚体(由两个拷贝的H_2A、H_2B、H_3和H_4组成)构成核小体的核心，核小体被DNA螺旋的~146个碱基片段包裹。 组蛋白的球状部分构成了每个核小体的核心，然而每个组蛋白都有一个非结构化的N-末端片段(所谓的“尾”)，可以进行广泛的翻译后修饰(PTM)。开放染色质(常染色质)由伸展开的核小体组成，使DNA暴露于蛋白质结合。另一方面，很难接触到的异染色质是由核小体凝聚成高阶纤维形成的。 图片来源：https://pubmed.ncbi.nlm.nih.gov/37700551/ 近日，来自波兹南医科大学的研究者们在Br J Pharmacol.杂志上发表了题为“Natural products modulating epigenetic mechanisms by affecting histone methylation/demethylation: targeting cancer cells”的文章，该研究揭示了天然产物通过影响组蛋白甲基化/去甲基化来调节表观遗传机制。 许多天然产物可以通过干扰细胞表观遗传机制发挥抗癌或化学预防作用。虽然大量的研究表明影响DNA甲基化和组蛋白乙酰化的相关性，但对组蛋白甲基化相关机制的影响往往被忽视。这可能与滞后的证据有关，即组蛋白甲基化写入者和擦除者的行为变化以及随后组蛋白甲基化特征的变化与癌症的发生有因果关系。然而，最近的动物研究表明，靶向组蛋白甲基化/去甲基化影响实验诱导的致癌过程。 现有数据表明，来自不同化学基团的许多天然化合物，包括绿茶多酚和其他黄酮类、姜黄素类、二苯乙烯类、酚酸、异硫氰酸酯、生物碱和萜类，可以影响组蛋白赖氨酸和精氨酸残基甲基化和去甲基化过程中关键酶的表达和活性。这些活性与肿瘤相关基因表达和功能变化的调节有关，包括减少细胞增殖和迁移，以及在各种癌症模型中促进细胞凋亡。 大多数研究集中于两种蛋白质-EZH2(H3K27甲基转移酶)和LSD1(H3K4/9去甲基酶)的表达和/或活性的调节，或者植物化学物质对组蛋白甲基化标志的全球水平的影响，而关于其他组蛋白甲基转移酶或去甲基酶的数据很少。虽然这一领域仍然相对未被探索，但本文旨在探讨天然产物对组蛋白甲基化/去甲基化相关酶的影响，以显示它们与癌症发生和癌症进展的相关性。 机制总结图 图片来源：https://pubmed.ncbi.nlm.nih.gov/37700551/ 综上所述，许多天然产物的活性与影响组蛋白甲基化和去甲基化相关的机制有关。然而，这一主题仍然非常未被探索，需要在这一领域进行进一步的研究。然而，组蛋白甲基化/去甲基化改变在肿瘤发生中的生物学意义是毋庸置疑的，这为癌症的预防和治疗提供了机制机会。（生物谷 Bioon.com） 参考文献 Dawid Dorna et al. Natural products modulating epigenetic mechanisms by affecting histone methylation/demethylation: targeting cancer cells. Br J Pharmacol. 2023 Sep 12. doi: 10.1111/bph.16237.

MONDAY, April 24, 2023 -- For patients with advanced melanoma, treatment with anti-programmed cell death 1 (anti-PD-1) results in improved response rate and longer progression-free survival for those with normal vitamin D levels, according to a study published online April 24 in Cancer . Lukasz Galus, M.D., from the Poznan University of Medical Sciences in Poland, and colleagues compared the effectiveness of anti-PD-1 therapy in patients with locally advanced, inoperable, or metastatic melanoma in relation to vitamin D levels. All patients received nivolumab or pembrolizumab as first-line therapy. The participants were divided into subgroups: 58 with reduced vitamin D levels, who did not receive supplementation or had ineffective supplementation, and 141 patients with normal vitamin D levels at baseline or obtained with supplementation. The researchers found that the response rate was 36.2 versus 56.0 percent in the group with low vitamin D levels and not supplemented compared with the group with normal baseline levels or a normal level obtained with supplementation. In these groups, progression-free survival was 5.75 and 11.25 months, respectively. In terms of overall survival, there was a trend toward improved survival for the group with normal vitamin D levels (27 versus 31.5 months). "The authors' opinion is that assessment of vitamin D levels and appropriate vitamin D supplementation should be considered in every patient qualified for treatment with anti–PD‐1 immunotherapy," the authors write. Several authors disclosed financial ties to the biopharmaceutical industry. Abstract/Full Text (subscription or payment may be required) Posted April 2023